We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Biotech Sector Set for Growth Amid Innovation and Investor Interest
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. The industry has recovered from a challenging 2024 and is poised for significant expansion led by advances in personalized medicine, AI-driven drug discovery, and growing demand for biologics. MarketsandMarkets predicted that the global biotech market would expand by a strong 13%, from $483.0 billion in 2024 to $546.0 billion in 2025. This expansion demonstrates the sector’s tenacity and promise for growth.
The anticipated shift in the Federal Reserve’s interest rate policies is a key driver of this upturn. Biotech is sensitive to changing rate patterns since it requires a large amount of money for costly R&D and clinical testing. Lower rates make more funding available, which helps biotech companies expand, draw in venture capital, and expedite drug development, according to Genetic Engineering and Biotechnology News. A rate drop, according to analysts, may release billions of dollars in investment funds that have been put aside for fledgling biotech firms looking for steady funding.
Investor interest in biotech equities is growing. Biotech is still a high-growth industry with many chances for risk-takers, despite brief ups and downs. The comeback of biotech has been noted by leading investment banks. Citing solid fundamentals, improved clinical outcomes, and a supportive regulatory environment, Goldman Sachs referred to it as an “undervalued opportunity.” According to the firm, biotech equities have tremendous upside potential and an “option-like structure,” particularly when interest rates decline. Analysts at JPMorgan anticipate a recovery in biotech funding at the same time, pointing to indications of stability in manufacturing and research sectors that were negatively impacted by earlier funding shortages. Industry analysts predict that declining interest rates and advantageous investment circumstances may reopen the IPO window for businesses looking for institutional support, even though biotech IPOs have been quiet since 2021.
As gene editing, AI-powered drug discovery, and precision medicine transform how we treat uncommon genetic illnesses, autoimmune diseases, and cancer, scientific advances are also propelling the expansion of biotech. Biotech firms are meeting medical demands in ways that were unthinkable a decade ago because of developments in CRISPR gene editing and cell treatments. Given this, we will take a look at some of the best promising stocks from the biotech sector.
Our Methodology
For this article, we shortlisted stocks that met the following criteria: a market capitalization of over $2 billion, coverage by at least 15 analysts, and a price target upside of more than 20%. We then ranked the selected stocks based on their price target upside, as determined by Wall Street analysts, as of March 21, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Is Moderna, Inc. (MRNA) a Promising Biotech Stocks According to Wall Street Analysts
A scientist studying a petri dish with magnifying glass in a laboratory setting.
Moderna, Inc. (NASDAQ:MRNA) is a biotech company that develops vaccines based on messenger RNA (mRNA) and stands eleventh on our list among the 12 most promising biotech stocks according to Wall Street analysts. The business has solid foundations, despite poor sales and slow market uptake of its new goods. It has a positive outlook because of its complex pipeline of pharmaceuticals undergoing clinical testing.
The company is developing its late-stage candidate pipeline to preserve its market share in 2025 for COVID-19 vaccinations. In the respiratory vaccine space, Moderna, Inc. (NASDAQ:MRNA) is also awaiting FDA approval for an expanded indication of its RSV vaccine. Additionally, it has applied for licensure of a combination influenza-COVID-19 vaccine supported by encouraging phase 3 research results.
Analysts are also optimistic about Moderna, Inc. (NASDAQ:MRNA) because of its non-respiratory portfolio, which includes cytomegalovirus (CMV) and norovirus vaccines. Additionally, mRNA-4157, which is being studied in partnership with Merck, exhibits promise across a range of malignant tumor types. The corporation’s capacity to introduce its mRNA technology into new markets is demonstrated by this varied pipeline, which positions it as a more established and varied commercial-stage biotech business.
Wall Street analysts have provided 12-month price targets for the stock, with an average target of $41.75. The forecasts range from a high of $78.00 to a low of $25.00. This suggests a potential 27.83% increase from Moderna, Inc. (NASDAQ:MRNA)’s current price of $32.66.
Overall, MRNA ranks 11th among the 12 most promising biotech stocks according to wall street analysts. While we acknowledge the potential of biotech companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MRNA but that trades at less than 5 times its earnings, check out our report about thecheapest AI stock.
